Primal Grow Pro Official Website › Blog › St John’s Wort And Your Prescription
St. John’s Wort And Your Prescription
St. John’s wort is the most interaction-prone herb in ordinary retail supply, and it turns up on a great many multi-ingredient supplement labels where nobody expects to meet it. This is what it does, which medicines it does it to, and what the one conversation worth having before the first capsule actually sounds like.
If you take any prescription medicine at all, name this herb specifically to whoever prescribes it before the first capsule, and name the herb rather than the product. Anyone writing prescriptions will recognise St. John’s wort immediately and will not recognise a brand name.
- St. John’s wort activates the pregnane X receptor, which induces the CYP3A4 enzyme and the P-glycoprotein transporter.
- Those two handle a very large share of prescription medicines. Inducing them means the medicine is cleared faster and its blood level falls.
- The documented list includes ciclosporin, hormonal contraceptives, warfarin, digoxin, tacrolimus, indinavir, alprazolam and simvastatin.
- A randomised trial of the contraceptive interaction found intracyclic bleeding rising from 35% to between 77 and 88 per cent.
- The degree of induction tracks the hyperforin content of the extract, so a small amount of a low-hyperforin preparation behaves differently from 900 mg of a standardised one.
- None of this makes the herb dangerous on its own. It makes it a herb that has to be declared.
What it actually does
For a botanical, the mechanism here is unusually well worked out, and that is part of why this particular interaction is taken as seriously as it is.
Inside the cell nucleus sits a receptor called PXR, which behaves like a master control for the machinery that clears foreign compounds out of the body. This herb turns it on. Turning it on raises production of CYP3A4 in the liver and the gut wall, and of P-glycoprotein, the transporter that pushes compounds back out of cells and back into the gut.
The consequence is straightforward and it runs in one direction. Medicines handled by either system are cleared from the body faster. Their blood levels fall. A dose that was working stops working, and the person taking it usually has no way of connecting that to a capsule they started a fortnight earlier.
Why falling levels are the dangerous direction
Most people, hearing about a drug interaction, imagine a level rising and causing toxicity. This one mostly does the opposite, and that is what makes it insidious.
A medicine that stops working does not announce itself. A transplant patient whose immunosuppressant level drops does not feel it happening. Somebody relying on a contraceptive does not get a warning. The failure is silent until its consequence is not.
Which medicines, and what was documented
A 2020 review in the British Journal of Pharmacology revisited the clinical relevance of these interactions and named the drugs. This is that list, with what was recorded against each.
| Medicine or class | What was documented | Why it matters |
|---|---|---|
| Ciclosporin | The 2020 clinical review records two heart transplant rejections associated with this interaction. | The most serious entry in the literature, and the reason this interaction is taught rather than merely noted. |
| Hormonal contraceptives | Reduced hormone exposure and a large rise in breakthrough bleeding, in two independent designs. | Covered in detail below. It is the best-characterised interaction of the set. |
| Warfarin | Named in the same review, alongside a wider supplement literature. | Anticoagulation is measured, so a change is detectable, and it needs the person holding the record. |
| Digoxin | Reduced blood levels through P-glycoprotein induction. | A narrow therapeutic index drug, where a modest fall in level is not a modest event. |
| Tacrolimus | Reduced levels, same mechanism as ciclosporin. | Another transplant medicine, with the same consequence if it falls. |
| Indinavir | Substantially reduced exposure. | An antiretroviral. Reduced exposure to this class has consequences beyond the individual taking it. |
| Alprazolam, simvastatin | Both named in the 2020 review as subject to CYP3A4 induction. | Common prescriptions, which is what makes checking worthwhile rather than academic. |
| Antidepressants | The herb has serotonergic activity of its own on top of its enzyme effects. | The one case where two separate mechanisms apply at once. |
Every entry is a documented property of St. John's wort as an ingredient. None of them describes a reported case involving any particular product.
Reading down the third column, a pattern appears. The medicines where this matters most are the ones where a modest fall in blood level is not a modest event: transplant immunosuppressants, anticoagulants, antiretrovirals, contraceptives. Those are also, unhelpfully, medicines people take for years and stop thinking about.
The NCCIH's page on the herb is a plain-language summary of the same territory and is worth a bookmark for anyone who wants a second source that is not a research paper.
The best-characterised interaction, in three studies
If one interaction deserves to be understood in detail rather than as an entry on a list, it is this one, because two independent designs reached the same conclusion and a systematic review then gathered the field.
| Study | Design | Amount used | What changed |
|---|---|---|---|
| Pfrunder and colleagues, 2003 | Randomised controlled trial, low-dose oral contraceptive | 300 mg extract two or three times daily | Intracyclic bleeding rose from 35% to between 77% and 88%. 3-ketodesogestrel exposure fell by about 42 to 44%. |
| Murphy and colleagues, 2005 | Pharmacokinetic study, norethindrone and ethinyl estradiol | Standardised extract | Altered hormone pharmacokinetics, changed ovarian activity and more breakthrough bleeding. |
| Berry-Bibee and colleagues, 2016 | Systematic review of the whole question | Across the included studies | Treats the interaction as established and clinically relevant. |
Two primary studies with different designs reaching the same conclusion, plus the review that gathered the field. This is what a well-characterised interaction looks like.
The first study is the striking one. Intracyclic bleeding, which is bleeding between periods, rose from 35 per cent to somewhere between 77 and 88 per cent depending on the arm. Hormone exposure fell by about 42 per cent.
Breakthrough bleeding is not itself the risk. It is a visible marker of something that is otherwise invisible, which is that the hormone level being relied on has dropped substantially.
This product is sold to adult men, and that does not settle the question. A supplement bottle lives in a bathroom cabinet or a kitchen cupboard shared with other people. Who it is for on this website treats a shared household as part of the answer rather than an afterthought.
Read the full Primal Grow Pro interaction list first
Every medicine St. John's wort is documented to interfere with, set out drug by drug with the study attached, before the first capsule rather than after it.
One bottle $69 · four bottles $196 · 60-day money-back guarantee
Order Primal Grow Pro On The Official WebsiteOne capsule a day · 30 per bottle · lot PRI-26/TH-6374
Why it appears on a vitality formula at all
The obvious question, having read the above, is what this herb is doing in a supplement sold for everyday male vitality.
The evidence base for St. John’s wort is almost entirely about mood. The Cochrane review pooled twenty-nine trials in 5,489 patients and found it superior to placebo and comparable to standard antidepressants in the included studies, with fewer dropouts for adverse effects. That is a substantial and generally positive literature.
Mood is a reasonable component of anything sold as vitality, and a formulator adding this herb is drawing on a real body of evidence. The difficulty is not that the ingredient is unjustified. It is that the ingredient arrives with a set of consequences that the front of a bottle rarely mentions, and that most buyers would want to know about.
Naming the ingredient, as this seller does, is the minimum and it is enough for a reader who already knows what the herb is. Flagging what it interacts with would be the thing that actually protects somebody who does not.
The nuance that cuts the other way
Everything above describes the herb at the amounts its own trials used, which is 600 to 900 milligrams a day of standardised extract. A multi-ingredient capsule is a different proposition and it is fair to say so.
The degree of enzyme induction tracks the hyperforin content of the preparation. A low-hyperforin extract induces less. A small amount induces less than a large one. Some preparations produce measurable interaction effects and some do not, and the difference is not the plant but the extract and the quantity.
On a label that prints no amounts, nobody outside the manufacturer can place the product on that scale. That is an argument for asking rather than an argument for assuming the worst, and it is one of the specific questions worth putting to a seller in writing before a large order. The seal audit on this website lists the others.
What the conversation sounds like
People avoid this conversation because they imagine it being long or awkward. It is neither, and it usually takes under a minute.
- Name the herb. “I want to start a supplement that contains St. John’s wort.” Not the brand. The herb is what will be recognised.
- List what you take. Everything, including the ones that feel too ordinary to mention. Contraceptives and statins are the two most often left out.
- Ask the direct question. “Does that interact with anything I am on?” The answer is usually immediate, because this is one of the interactions every prescriber knows.
- Ask what to watch for if the answer is yes but not absolute. Some interactions mean no. Some mean monitor. Knowing which one you have been given is the whole point of asking.
- Write down what you were told. A date and a sentence. It is the thing you will want in six months when a different prescription is added.
A checklist for anyone taking anything
- Read the full ingredient list of every supplement you take, not just the front of the bottle. This herb turns up on mood formulas, sleep formulas and vitality formulas alike.
- Treat a new prescription as a new decision about the supplement. The dangerous case is a medicine started three months into a routine, when nobody thinks to mention the capsule.
- Do not assume a small amount is a safe amount. Without a printed quantity, nobody can tell you which you have, and the induction effect is a property of the extract as much as of the weight.
- Keep the bottle labelled and out of a shared supplement drawer. The person it matters most for may not be the person who bought it.
- Tell a surgical or dental team what you take, by ingredient. Two weeks before, as a matter of routine.
If you take nothing at all
Then most of this article does not apply to you, and that is worth saying explicitly rather than leaving a reader with an undifferentiated sense of alarm.
St. John’s wort taken on its own by somebody on no medication is an ordinary botanical with a large, generally positive evidence base and a modest side-effect profile. Photosensitivity and mild stomach effects are the usual entries.
The whole of the concern above is about combinations. It is a herb that has to be declared, not a herb that has to be avoided, and the difference between those two statements is the reason this article is eight sections long instead of one sentence.
References
- Nicolussi S, Drewe J, Butterweck V, et al. Clinical relevance of St. John's wort drug interactions revisited. Br J Pharmacol. 2020;177(6):1212-1226. PMID 31742659. https://pubmed.ncbi.nlm.nih.gov/31742659/
- Berry-Bibee EN, Kim MJ, Tepper NK, et al. Co-administration of St. John's wort and hormonal contraceptives: a systematic review. Contraception. 2016;94(6):668-677. PMID 27444983. https://pubmed.ncbi.nlm.nih.gov/27444983/
- Pfrunder A, Schiesser M, Gerber S, et al. Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial. Br J Clin Pharmacol. 2003;56(6):683-90. PMID 14616430. https://pubmed.ncbi.nlm.nih.gov/14616430/
- Murphy PA, Kern SE, Stanczyk FZ, et al. Interaction of St. John's Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding. Contraception. 2005;71(6):402-8. PMID 15914127. https://pubmed.ncbi.nlm.nih.gov/15914127/
- Linde K, Berner MM, Kriston L. St John's wort for major depression. Cochrane Database Syst Rev. 2008;2008(4):CD000448. PMID 18843608. https://pubmed.ncbi.nlm.nih.gov/18843608/
- St. John's Wort: Usefulness and Safety. National Center for Complementary and Integrative Health, National Institutes of Health. https://www.nccih.nih.gov/health/st-johns-wort